Daniel O’Day
Chairman and Chief Executive Officer
Daniel O'Day serves as Chairman of the Board of Directors and Chief Executive Officer at Gilead Sciences. Dan joined Gilead in March 2019 after more than three decades at Roche Pharmaceuticals where he also served as Chief Executive Officer. During his career at Roche, he held a number of prior executive positions in the company's pharmaceutical and diagnostics divisions in North America, Europe and Asia. He was a member of Roche's Corporate Executive Committee and served on several public and private boards, including Genentech, Flatiron Health and Foundation Medicine. Dan holds a bachelor's degree in biology from Georgetown University and an MBA from Columbia University in New York. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America organization, Galapagos NV and Georgetown University.
-
Daniel O’Day
Chairman and Chief Executive Officer
-
Jacqueline K. Barton, PhD
Professor, California Institute of Technology
-
Jeffrey A. Bluestone, PhD
President and Chief Executive Officer, Sonoma Biotherapeutics; A.W. and Mary Margaret Clausen Distinguished Professor in the Diabetes Center at University of California San Francisco
-
Sandra J. Horning, MD
Retired, Chief Medical Officer, Roche, Inc.; Emerita Professor, Stanford University
-
Kelly A. Kramer
Retired, Executive Vice President and Chief Financial Officer, Cisco Systems, Inc.
-
Kevin E. Lofton
Lead Independent Director; Retired Chief Executive Officer, CommonSpirit Health
-
Harish Manwani
Retired Chief Operating Officer, Unilever
-
Javier J. Rodriguez
Chief Executive Officer, DaVita Inc.
-
Anthony Welters
Chairman and Chief Executive Officer, CINQ Care Inc.; Executive Chairman, BlackIvy Group, LLC; Chairman, Somatus Inc.